ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun1067

Pathophysiological Mechanisms of Congestive Heart Failure: A Comprehensive Review

Km Pooja Singh[1*]; Neha Kannojiya[2]; Arpita Singh[3]; Urmila Nishad[4]; Dr. Rahul Prem Kumar Mishra[5]

[1]Student M Pharm Pharmacology, Seth Vishambhar Nath Institute of Pharmacy, Barabanki
[2]Student M Pharm Pharmaceutics, Seth Vishambhar Nath Institute of Pharmacy, Barabanki
[3]Director, Seth Vishambhar Nath Institute of Pharmacy, Barabanki
[4]Guide, Seth Vishambhar Nath Institute of Pharmacy, Barabanki
[5]Guide, Seth Vishambhar Nath Institute of Pharmacy, Barabanki

Corresponding Author: Km Pooja Singh

Publication Date: 2025/06/23

Abstract: Congestive heart failure (CHF), also known as heart failure, is a complex debilitating clinical syndrome characterized by the heart's inability to pump sufficient blood to meet the body's metabolic demands or to do so only at elevated filling pressures, this results in a cascade of compensatory mechanisms and ultimately in systemic and pulmonary congestion. This review delves into the intricate pathophysiological mechanisms underpinning CHF, exploring the interplay between various factors, including myocardial dysfunction, neurohormonal activation, remodeling processes, and the resulting clinical manifestations. We will examine the initial triggers, the compensatory mechanisms that ultimately contribute to the progression of the disease, and the key signaling pathways involved. A thorough understanding of these mechanisms is crucial for developing targeted therapeutic strategies to alleviate symptoms, improve prognosis, and ultimately prevent the advancement of CHF. To start the best course of treatment for each patient, it is crucial to comprehend the underlying pathophysiology of heart failure. Furthermore, avoiding cardiovascular risk factors is necessary to lower the risk.

Keywords: *Congestive Heart Failure, Pathophysiology, Myocardial Dysfunction, Neurohormonal Activation, Cardiac Remodeling.*

How to Cite: Km Pooja Singh; Neha Kannojiya; Arpita Singh; Urmila Nishad; Dr. Rahul Prem Kumar Mishra (2025) Pathophysiological Mechanisms of Congestive Heart Failure: A Comprehensive Review. *International Journal of Innovative Science and Research Technology*, 10(6), 1410-1416. https://doi.org/10.38124/ijisrt/25jun1067

I. INTRODUCTION

The complicated clinical illness known as heart failure (HF), or congestive heart failure (CHF), is marked by the incapacity of the heart to pump blood efficiently because of anatomical or functional abnormalities. Congested any functional or anatomical hearts condition that impairs the ventricle's capacity to fill or eject blood can result in heart failure, a complicated clinical illness. It is characterised by inadequate heart function, which decreases the body's blood supply. Any condition that slows down the input or outflow of blood into the systemic circulation leads to CHF. Although ischaemic heart disease is the most constant cause of heart failure (HF), myocarditis, valve disease, and hypertension are other contributing causes. Heart failure is a prevalent condition that has a high rate of morbidity and death worldwide. With an estimated 26 million cases globally, CHF lowers functional ability, raises healthcare expenses, and has a major negative impact on quality of life.[1]

This needs a comprehensive knowledge of the illness, including its aetiology, pathophysiological processes, diagnostic techniques, pharmacological treatments, lifestyle changes, and the exciting field of new therapeutics. Numerous variables, such as age, lifestyle, and prior medical disorders, significantly impact the occurrence of heart failure. The load of HF is predicted to significantly increase as the ageing population grows and cardiovascular risk factors become more prevalent.[2]

Consolidating and analysing the body of knowledge about heart failure (HF), specifically identifying its aetiology, deciphering pathophysiological mechanisms, navigating diagnostic modalities, investigating pharmacological

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun1067

interventions, promoting lifestyle changes, and mapping the future of emerging therapies are the main goals of this thorough review. The incapacity of the heart to adequately pump blood to fulfil the body's metabolic needs is the characteristic of heart failure (HF), a complicated clinical disease. This disorder appears when the heart's ability to pump blood is disturbed, resulting in symptoms including exhaustion, fluid retention, and shortness of breath.[3,4]

Coronary artery disease is the most prevalent cause of congestive heart failure (CHF). Atheroma or plug formation in the arteries supplying blood to the heart is a symptom of coronary artery disease (CAD). It lowers blood pressure and reduces the amount of oxygen available. Arrhythmia, cardiomyopathy, hypertension, lung conditions, obesity, and endocarditis are other reasons.

The substantial influence that HF has on public health is shown by its epidemiology. Over 26 million individuals worldwide involve with HF, which is thought to afflict 1% to 2% of adults. As people age, the incidence and prevalence of heart failure (HF) rise, making it a major health issue among the aged peoples. The load of HF is expected to increase in the upcoming years because to the growing ageing population and the growth in cardiovascular risk factors.[5]

➢ *Risk Factors*

- Hypotension
- Heart attack
- Age Family history
- Fluid retention
- Bradycardia
- Coronary Artery Disease
- Smoking tobacco
- Diabetes
- Obesity
- Increase in B.P
- Infections such as HIV or COVID-19

II. ETIOLOGY OF HEART FAILURE

The most common cause of HF is coronary artery disease (CAD), which leads to ischaemic heart disease, however there are other reasons as well. Every attempt should be made to identify the underlying reasons in order to help guide treatment efforts. The aetiologies can be broadly classified as intrinsic heart disease, myocarditis-related, valvular, congenital, infiltrative, and high output failure resulting from systemic illness.[6]

A wide range of etiological variables contribute to the development of heart failure (HF), making it a complex disorder. Comprehending these elements is essential for creating preventative and treatment plans that work.

➢ *Genetic Predispositions*

The probability of having HF might be considerably raised by a family history of the illness. In certain instances, genetic alterations that impact the anatomy and function of the heart are involved. Some individuals may also inherit a predisposition to factors such as hypertension or diabetes, which can further exacerbate the risk.[7]

➢ *Hypertension*

The heart's capability to pump blood can be impacted by structural changes brought on by high blood pressure over time. Hypertension is a valuable risk factor for the progression of HF. Hypertension can potentially result in CHF. The heart may have to do harder work to pump blood, which might lead to congestive heart failure. Hypertension causes changes in the structure and function of myocardium, such as left ventricular hypertrophy.[8]

➢ *CAD*

Myocardial infarction brought on by atherosclerosis and ischaemic heart disease can affect cardiac function. Since CAD is a key contributor to cause heart failure, cardiovascular health is crucial.[9]

➢ *Valvular Heart Disease*

Valve disease is another common intrinsic cardiac condition that can lead to heart failure. Rheumatic heart disease is the leading cause of valvular heart disease in children and young people worldwide. It is caused by an immune response to group A Streptococcus and mostly causes mitral and aortic stenosis. Age-related degeneration is the most common cause of valvular disease, which most commonly affects the aortic valve. Women are more likely to have mitral valve rheumatic heart disease or mitral valve prolapse, whereas males are more likely to have aortic valve conditions such regurgitation or stenosis. Endocarditis is also more common in men.[10]

➢ *Myocarditis and Cardiomyopathies*

Heart function can be compromised by a number of cardiomyopathies including myocarditis, an inflammation of the heart muscle. Cardiomyopathy is a broad category of diseases characterised by larger ventricles with impaired function that are not connected to secondary causes such ischaemic heart disease, valvular heart disease, hypertension, or congenital heart disease. The most common types of cardiomyopathies include hypertrophic, dilated, restricted, arrhythmogenic, and left ventricular noncompaction. Myocarditis, ventricular remodelling, and cardiac dysfunction are characteristics of inflammatory cardiomyopathy. The another most common cause is viral infection. Infections with bacteria, fungi, or protozoa, immune-mediated diseases, and hazardous substances or drugs are other reasons.[11]

➢ *Diabetes Mellitus*

A metabolic disorder called diabetes raises the risk of heart problems, including HF. The heart undergoes structural and functional alterations as a result of insulin resistance and hyperglycemia.[12]

➢ *Obesity*

One of the main causes of CHF in people younger than forty is obesity. Obesity alone is considered to be responsible for up to 10% of CHF cases. Obese patients are more prone to have HFpEF, which may be caused by adipose-produced

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun1067

cytokines such TNFα, IL-1b, and IL-8. Natriuretic peptides are also broken down by adipose tissue.[13]

➢ *Tachycardia and Arrhythmia*

A low-output CHF condition might be brought on by tachycardia or an arrhythmia. All of the heart's chambers expand, and the biventricular wall's thickness usually stays the same or decreases. Electrophysiologic changes accompany this, including longer-lasting and smaller-amplitude action potentials from the myocytes. The typical neurohormonal response that leads to CHF is triggered by each of these factors. These changes are often reversible with rate regulation due to myocardial hibernation.[14]

III. PATHOPHYSIOLOGICAL MECHANISMS

Heart failure happens when the heart muscle's structure changes and it is unable to pump enough blood, which is vital to the body. Blood may back up in this situation, and fluid may accumulate in the arms, legs, or lungs, which is a sign of congestive heart failure. Complex pathologic processes that affect the anatomy and physiology of the heart are involved in the development of HF. Analysing these procedures is crucial to establishing focused treatments and enhancing patient results.

A. Initiating Events and Cardiac Dysfunction

The development of CHF is typically triggered by an initial insult to the heart, which can stem from a variety of underlying etiologies. These can generally be categorized into.

- Myocardial Damage: This includes ischemic heart disease (IHD), which is the major cause of CHF, where myocardial infarction (MI) and chronic ischemia impair the contractility and structural integrity of the heart. Other causes include cardiomyopathies (dilated, hypertrophic, restrictive), myocarditis (inflammation of the heart muscle), and infiltrative diseases like amyloidosis. These conditions directly damage or weaken the myocardium, leading to reduced contractile force and impaired ventricular function.
- Volume Overload: Conditions such as valvular regurgitation (mitral, aortic, tricuspid), high-output states (e.g., anemia, hyperthyroidism), and congenital shunts (e.g., atrial septal defect) lead to chronic volume overload of the ventricle. This prolonged increase in preload initially enhances contractility (Frank-Starling mechanism) but eventually leads to chamber dilation and eccentric hypertrophy, impairing effective pumping.
- Pressure Overload: The heart is under constant pressure from pulmonary hypertension, aortic stenosis, and systemic hypertension, forcing it to work harder to eject blood. This initially results in concentric hypertrophy, increasing the wall thickness of the ventricle. While initially compensatory, prolonged pressure overload leads to diastolic dysfunction, increased myocardial oxygen demand, and ultimately, systolic dysfunction.
- Restricting Filling: Conditions such as pericardial constriction, restrictive cardiomyopathy, and advanced hypertrophic cardiomyopathy impair ventricular filling during diastole. This cause to elevated filling pressures, which contribute to pulmonary and systemic congestion, even when systolic function is comparatively normal.

The initial insult, regardless of its cause, initiates a series of pathophysiological changes that contribute to the progression of CHF. This includes changes in myocardial contractility, relaxation, and the overall structure and function of the heart.[15,16]

B. Maladaptive Cardiac Remodeling

Cardiac remodeling refers to the complex and dynamic process involving alterations in the heart's size, shape, structure, and function brought on by trauma or long-term stress. While initially intended as a compensatory mechanism, it ultimately becomes maladaptive and contributes to the continue development of CHF. Key aspects of cardiac remodeling include:

- Myocyte Hypertrophy: Increased afterload and preload stimulate myocyte hypertrophy, increasing the size of individual heart muscle cells. This can be concentric (pressure overload) or eccentric (volume overload). Hypertrophied myocytes often exhibit altered gene expression, decreased contractile function, and increased susceptibility to apoptosis.
- Extracellular Matrix (ECM) Remodeling: The ECM, composed of collagen, fibronectin, and other proteins, provides structural support to the myocardium. In CHF, there is an imbalance between ECM synthesis and degradation, leading to increased collagen deposition and myocardial fibrosis. Fibrosis increases the risk of arrhythmias by stiffening the heart, affecting diastolic function, and interfering with electrical conduction.
- Myocyte Loss and Apoptosis: Necrosis and myocyte apoptosis (programmed cell death) are caused by prolonged stress and ischaemia. This loss of contractile tissue impairs systolic function and contributes to chamber dilation.
- Chamber Dilation and Sphericalization: Over time, the initial hypertrophy gives way to chamber dilation, particularly in the left ventricle. This dilation reduces the efficiency of contraction and leads to increased wall stress (Laplace's Law). The ventricle also tends to become more spherical, further diminishing its pumping efficiency.

Cardiac remodeling is driven by a complex interplay of mechanical stretch, neurohormonal activation, and inflammatory mediators. Understanding the process of molecular mechanisms regulating remodeling is important for developing therapies to prevent or reverse this process.[17,18]

C. Neurohormonal Activation

As cardiac output falls, the body activates various neurohormonal systems in an attempt to maintain blood pressure and perfusion to vital organs. While initially beneficial, prolonged activation of these systems contributes to the progression of CHF. Key neurohormonal pathways involved in CHF include:

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun1067

- Sympathetic Nervous System (SNS): The SNS is activated by decreased cardiac output, which causes catecholamines (epinephrine and norepinephrine) to be released in greater amounts. In the beginning, this improves cardiac output by raising heart rate, contractility, and vasoconstriction. On the other hand, prolonged SNS activity causes arrhythmias, increased cardiac oxygen demand, and further myocardial damage. Down regulation of beta adrenoceptors in the heart also diminishes the responsiveness to adrenergic stimulation over time.
- Renin Angiotensin Aldosterone System (RAAS): The RAAS is activated by decreased renal perfusion, which raises the synthesis of aldosterone and angiotensin II. Strong vasoconstrictor angiotensin II promotes myocyte hypertrophy and raises afterload. Aldosterone increases preload and contributes to congestion and oedema by encouraging the retention of water and salt. Aldosterone and angiotensin II both play a role in inflammation and myocardial fibrosis.
- Natriuretic Peptides (ANP and BNP): Increased atrial and ventricular stretch stimulates the release of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), respectively. These peptides promote vasodilation, natriuresis (sodium excretion), and diuresis (water excretion), counteracting the effects of the RAAS and SNS. BNP also inhibits renin and aldosterone release. However, in CHF, the ability of natriuretic peptides to counteract the effects of the other neurohormonal systems is overwhelmed. Furthermore, impaired responsiveness to natriuretic peptides may develop.
- Endothelin-1 (ET-1): Endothelial cells release the potent vasoconstrictor endothelin in response to various stimuli, including angiotensin II and mechanical stretch. ET-1 contributes to increased afterload, myocardial hypertrophy, and fibrosis.
- Vasopressin (Antidiuretic Hormone - ADH): Released in response to elevated plasma osmolality and lowered blood pressure, vasopressin promotes reabsorption of water in the kidneys, contributing to increased blood volume and hyponatremia (low sodium levels).

Targeting these neurohormonal systems with medications like ACE inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and neprilysin inhibitors (ARNIs) has been shown to improve outcomes in CHF patients.[19,20]

D. Impact on Peripheral Circulation and Organ Function

CHF's impact extends beyond the heart, affecting peripheral circulation and the function of various organs:

- Fluid Retention and Edema: Blood backs up into the systemic and pulmonary circulation if the pumping ability of heart is decreased. This increased venous pressure and cause fluid leakage from the capillaries into the interstitial space, resulting in peripheral edema (swelling in the legs, ankles, and abdomen) and pulmonary edema (fluid accumulation in the lungs).
- Renal Dysfunction: Decreased cardiac output causes renal perfusion to drop, which triggers the RAAS and encourages water and salt retention. Chronic renal hypoperfusion can also lead to cardiorenal syndrome, where worsening heart failure leads to worsening renal function, and vice versa.
- Hepatic Congestion: Right sided heart failure can lead to congestion of the liver, causing increase in size of liver, ascites (fluid accumulation in the abdominal cavity), and even liver damage.
- Skeletal Muscle Dysfunction: CHF leads to decreased skeletal muscle blood flow and oxygen delivery, contributing to muscle fatigue, weakness, and reduced exercise tolerance. Changes in muscle metabolism, including increased anaerobic metabolism, also contribute to these symptoms.
- Pulmonary Congestion and Respiratory Distress: Breathlessness (dyspnoea), orthopnea (shortness of breath when lying down), and paroxysmal nocturnal dyspnoea (sudden start of shortness of breath during sleep) are all symptoms of left-sided heart failure, which results in pulmonary congestion. Hypoxaemia, or low blood oxygen levels, is another consequence of pulmonary congestion's impairment of gas exchange.
- Cognitive Impairment: Reduced cerebral blood flow and chronic hypoxemia in CHF patients can contribute to cognitive impairment, including memory problems and difficulty concentrating.[21,22]

E. Diastolic Dysfunction

While often associated with systolic dysfunction (reduced ejection fraction), CHF can also occur solely due to diastolic dysfunction (preserved ejection fraction, HFpEF). Despite good systolic function, diastolic dysfunction is the inability of the ventricles to relax and fill during diastole, which results in increased filling pressures and pulmonary congestion. Key mechanisms contributing to diastolic dysfunction include:

- Myocardial Stiffness: Increased myocardial stiffness due to fibrosis, hypertrophy, and altered calcium handling impairs ventricular relaxation and filling.
- Impaired Myocardial Relaxation: Abnormalities in calcium handling within the myocytes, particularly impaired calcium reuptake by the sarcoplasmic reticulum, contribute to slowed ventricular relaxation during diastole.
- Increased Wall Thickness: Concentric hypertrophy increases ventricular wall thickness, reducing ventricular compliance and impairing filling.
- Pericardial Restraint: Conditions that restrict ventricular filling, such as pericardial constriction, can contribute to diastolic dysfunction.

The complicated illness known as HFpEF has several underlying causes, including as diabetes, obesity, hypertension, and chronic kidney disease. Its

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun1067

pathophysiology is less well understood than that of systolic heart failure, and effective treatments are still lacking.[23,24]

F. Clinical Manifestations

The clinical manifestations of CHF are a direct consequence of the underlying pathophysiology.

- Dyspnea: Shortness of breath due to pulmonary congestion.
- Fatigue: Generalized weakness and exhaustion due to inadequate oxygen delivery to the tissues.
- Edema: Swelling of the ankles and legs (peripheral edema) due to fluid retention.
- Cough: May be dry or productive, particularly at night, due to pulmonary congestion.
- Paroxysmal Nocturnal Dyspnea (PND): Sudden onset of severe shortness of breath that awakens the patient from sleep, requiring them to sit or stand up to breathe.
- Other Symptoms: Include chest pain, palpitations, abdominal distension, and weight gain.

IV. DIAGNOSIS AND TESTS

The diagnosis of CHF is crucial for understanding or determining the illness or causal cause. It aids in selecting the best medical course of treatment. Healthcare professionals mostly enquire about your symptoms and medical history. Congestive heart failure can be diagnosed by a number of techniques, including blood tests, cardiac catheterisation, chest X-rays, echocardiograms, heart MRIs, and electrocardiograms.

V. MANAGEMENT OF CONGESTIVE HEART FAILURE

Congestive heart failure cannot be cured with a single therapy. Relieving symptoms and stopping the development of CHF are the primary goals of therapy. The course of treatment is determined by the patient's health, symptoms, heart failure type, and stage. Reducing hospitalisations, improving cardiac mortality, and improving symptoms and quality of life are the objectives of treatment for chronic heart failure. The goal of pharmacologic therapy is to manage symptoms and start and increase medications that lower HF mortality and morbidity.[25]

The use of drugs to alleviate symptoms and lower the risk of hospitalisation and mortality is a crucial part of managing CHF. These drugs include aldosterone antagonists, beta blockers, angiotensin receptor blockers (ARBs), diuretics, and angiotensin-converting enzyme (ACE) inhibitors. It has been demonstrated that using these drugs together, in accordance with recommended protocols, can effectively lower morbidity and fatality rates in patients with congestive heart failure.[26]

In addition to medication and device therapy, lifestyle changes such as salt restriction, fluid restriction, and regular exercise are also important components of CHF management. Patients should also be educated about the symptoms of worsening heart failure, and should be advised to found medical attention promptly if these occur. Lifestyle modifications are crucial in the management of CHF. These modifications include:[27]

- Dietary restrictions: Patients with CHF should limit their intake of salt to less than 2,000 mg per day and consume a heart-healthy rich diet in fruits, vegetables, whole grains, and lean proteins.
- Fluid restriction: Patients with CHF should limit their intake of fluid to 1.5-2 liters per day to prevent fluid overload.
- Exercise: Regular physical activity can improve symptoms, quality of life, and exercise capacity in patients with CHF. A supervised exercise program is recommended for patients with CHF.

Structured education and it has been demonstrated that self-management programs help CHF patients achieve better results. Usually, these programs offer information regarding the illness, medication management, diet and exercise, and symptom recognition and management. They also provide patients with the tools and support they need to manage their condition effectively.

Another important aspect of CHF management is the coordination of care between different healthcare professionals, such as cardiologists, primary care doctors, and specialists like nutritionists and nurses. This coordination is essential to ensure that patients receive the appropriate care and follow-up, and to prevent unnecessary hospitalizations.

The management of CHF is complex and involves a combination of lifestyle modifications, pharmacological therapies, device based treatments, and surgical interventions. Future directions in this field include stem cell therapy, gene therapy, and personalized medicine. Despite advances in therapy, CHF remains a significant public health problem, and further research is needed to improve better outcomes for patients with this condition.

VI. CONCLUSION

Congestive heart failure is a medical disorder when structural or functional abnormalities reduce the heart's ability to fill and pump blood and it is is a complex syndrome driven by a multitude of interacting pathophysiological mechanisms. Myocardial dysfunction, neurohormonal activation, cardiac remodeling, and inflammatory processes all contribute to the progression of the disease. The complexities of aetiology, pathophysiological processes, diagnostic techniques, pharmacological treatments, lifestyle changes, and new therapeutic approaches have all been covered in this thorough study. A comprehensive understanding of these mechanisms is essential for developing effective strategies to prevent, diagnose, and treat CHF. Continued research is crucial to identify novel therapeutic targets and improve the outcomes for patients with this debilitating condition.

➢ *Conflict of Interest*

The authors have no conflicts of interest.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun1067

REFERENCES

[1]. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]

[2]. Tillman F, Kim J, Makhlouf T, et al. A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans. Ther Adv Cardiovasc Dis. 2019;13:1753944719840192.

[3]. van Heerebeek L, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966–73.

[4]. Czepluch FS, Wollnik B, Hasenfuß G. Genetic determinants of heart failure: facts and numbers. ESC Heart Failure. 2018;5:211–7.

[5]. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149–54.

[6]. Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

[7]. Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021;11:263–76. Ponikowski P, Voors AA, Anker SD, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

[8]. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]

[9]. Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol. 2015;6:187–214.

[10]. Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]

[11]. Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

[12]. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti hyperglycaemic drug therapy. Lancet. 2015;385:2107–17.

[13]. Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]

[14]. Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]

[15]. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995–2008

[16]. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

[17]. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9:e1001204.

[18]. Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]

[19]. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

[20]. Verma S, McMurray JJV. SCGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–17

[21]. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

[22]. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]

[23]. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]

[24]. Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 2019;18:129.

[25]. Richards AM. The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides. Heart. 1996;76:36–44

[26]. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–11.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun1067

[27]. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114:2138–47.